Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Humulin M5
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Humulin M5 is a premixed formulation of human insulin consisting of 50% regular (short-acting) insulin and 50% NPH (intermediate-acting) insulin. Developed by Eli Lilly & Co., it is produced using recombinant DNA technology. It is indicated for the treatment of diabetes mellitus to improve glycemic control. The regular insulin component provides a rapid onset of action to manage postprandial glucose, while the NPH component provides a prolonged effect for basal coverage.
- Brand names
- Humulin M5
- Other names
- Humulin 50/50
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Humulin M5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humulin M5.